Skip to main content
main-content

Melanoma

13-06-2017 | Melanoma | News | Article

ASCO 2017

Nivolumab, ipilimumab duo elicits durable intracranial metastatic melanoma response

Patients with melanoma and untreated, asymptomatic brain metastases benefit from treatment with a combination of nivolumab and ipilimumab, suggest the results of the ABC and CheckMate 204 trials.

Source:

J Clin Oncol 2017; 35: 9507, 9508

19-05-2017 | Oncology | News | Article

In other news

Here we report on osteoporosis therapy in breast cancer patients, the feasibility of an alternative formulation of rituximab in follicular lymphoma, the effects of extended use of anamorelin on lung cancer-related cachexia, and the 3-year results of the COMBI-d trial.

19-04-2017 | Melanoma | News | Article

Editor's pick

Surgical resection still important in abdominal melanoma metastases

Patients who undergo surgical resection of abdominal visceral melanoma metastases have significantly better overall survival than those who do not, and the outcome is not greatly improved by modern systemic treatments, study findings indicate.

Source:

JAMA Surg 2017; Advance online publication

14-03-2017 | Melanoma | News | Article

Binimetinib extends NRAS-mutated metastatic melanoma PFS

Binimetinib could be incorporated into the treatment pathway of patients with advanced melanoma harboring NRAS mutations, say researchers who found a progression-free survival benefit with the MEK inhibitor over dacarbazine.

Source:

Lancet Oncol 2017; Advance online publication

01-03-2017 | Melanoma | News | Article

Large-scale melanoma screening ‘feasible’ in large healthcare systems

The rate of melanoma diagnoses can be doubled with routine screening by full-body skin examination and is feasible within a large healthcare system, US study data show.

Source:

JAMA Oncol 2017; Advance online publication

image credits